González RC, González IM, Duran JSE, Hernández GJG, Guerrero MB, Arenas GR

Language: Spanish
References: 20
Page: 472-478
PDF size: 310.29 Kb.

ABSTRACT

Objective: To determine the incidence, risk factors, clinical findings and outcome of patients at Hospital Juarez of Mexico.
Materials and Methods: Retrospective, observational, cross-sectional, non-experimental, single-center and analytical study was done including the records of patients with direct examination, culture or histopathological study positive for mucormycosis. The incidence by year and demographic and clinical characteristics were studied from January 2017 to December 2022 at the Hospital Juarez of Mexico.
Results: A total of 14 patients with mucormycosis were identified. The median age was 51 years, and the majority were women (n = 9). The site of involvement was rhinoorbito- cerebral mucormycosis in the entire sample. Eleven patients had uncontrolled diabetes mellitus. Annual cases of mucormycosis increased notably at the end of the COVID-19 pandemic during 2022.
Conclusions: Mucormycosis is an invasive fungal disease most seen in immunocompromised patients. In this study, its highest prevalence was in decompensated diabetes mellitus and the clinical variety was rhino-orbito-cerebral. An increase was noted at the end of the COVID-19 pandemic.

REFERENCES

1. Reid G, Lynch JP, Fishbein MC, Clark NM. Mucormycosis.Semin Respir Crit Care Med 2020; 41 (1): 99-114. doi:10.1055/s-0039-3401992

2. Skiada A, Drogari-Apiranthitou M, Pavleas I, Daikou E,Petrikkos G. Global cutaneous mucormycosis: A systematicreview. J Fungi 2022; 8. doi: 10.3390/jof8020194

3. Bonifaz A, Tirado-Sánchez A, Hernández-Medel ML, KassackJJ, et al. Mucormycosis with cutaneous involvement. Aretrospective study of 115 cases at a tertiary care hospitalin Mexico. Australas J Dermatol 2021; 62 (2): 162-7. doi:10.1111/ajd.13508

4. Romero-Zamora JL, Bonifaz A, Sánchez CJ, Lagunas-RamírezA, Hidalgo-Loperena H. Mucormicosis rinocerebral. Reportede doce casos. Rev Med Hosp Gen Mex 2000; 63(3): 178-184.

5. Castillo Garcia AL. Experiencia de mucormicosis en elHospital Juárez de México. Medicina interna. Rev HospJua Mex 2004; 71 (1): 3-13.

6. Nucci M, Engelhardt M, Hamed K. Mucormycosis inSouth America: A review of 143 reported cases. Mycoses.Blackwell Publishing Ltd; 2019; 62: 730-8. doi: 10.1111/myc.12958.

7. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, etal. Global guideline for the diagnosis and management ofmucormycosis: an initiative of the European Confederationof Medical Mycology in cooperation with the Mycoses StudyGroup Education and Research Consortium. Lancet Infect Dis2019; 16: e405-21. doi: 10.1016/S1473-3099(19)30312-3

8. Jiang N, Zhao G, Yang S, Lin J, Hu L, et al. A retrospectiveanalysis of eleven cases of invasive rhino-orbito-cerebralmucormycosis presented with orbital apex syndromeinitially. BMC Ophthalmol 2016; 16 (1). doi: 10.1186/s12886-016-0189-1

9. Walther G, Wagner L, Kurzai O. Updates on the taxonomyof mucorales with an emphasis on clinically important taxa.J Fungi 2019; 5. doi: 10.3390/jof5040106

10. Gorjón PS, Pérez PB, Caletrío ÁB, Muñoz Herrera ÁM, et al.Rhino-orbito-cerebral mucormycosis, a retrospective studyof 7 cases. Acta Otorrinolaringologica (English Edition)2010; 61 (1): 48-53. doi: 10.1016/s2173-5735(10)70008-9

11. Zobairy H, Salem MM, Ghajarzadeh M, Mirmosayyeb O,Mirsalehi M. Diabetes mellitus and other underlying conditionsin patients with coronavirus disease 2019 associatedrhino-orbito-cerebral mucormycosis: a systematic reviewand meta-analysis. J Laryngol Otol 2022; 136: 788-98. doi:10.1017/S0022215122001074

12. Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO,Sánchez-Nuño YA, et al. Host-pathogen molecular factorscontribute to the pathogenesis of Rhizopus spp. in diabetesmellitus. Curr Trop Med Rep 2021; 8: 6-17. doi: 10.1007/s40475-020-00222-1

13. Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, Rendón-Ramírez EJ, et al. Clinical features andoutcome of mucormycosis. Interdiscip Perspect Infect Dis2014; 2014. doi: 10.1155/2014/562610

14. Shrestha DB, Budhathoki P, Raut S, Adhikari S, et al. Newonsetdiabetes in COVID-19 and clinical outcomes: Asystematic review and meta-analysis. World J Virol 2021;10 (5): 275-87. doi: 10.5501/wjv.v10.i5.275

15. Özbek L, Topçu U, Manay M, Esen BH, et al. COVID-19-associated mucormycosis: a systematic review andmeta-analysis of 958 cases. Clin Microbiol Infect 2023; 29:722-31. doi: 10.5501/wjv.v10.i5.275

16. Watanabe A, So M, Mitaka H, Ishisaka Y, et al. Clinicalfeatures and mortality of COVID-19-associated mucormycosis:A systematic review and meta-analysis.Mycopathologia 2022; 187: 271-89. doi: 10.1007/s11046-022-00627-8

17. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, et al.The emergence of COVID-19 associated mucormycosis: areview of cases from 18 countries. Lancet Microb 2022;e543-52. doi: 10.1016/S2666-5247(21)00237-8

18. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, et al. Challengesin the diagnosis and treatment of mucormycosis.Medical Mycology. Oxford University Press; 2018; 56:S93-101. doi: 10.1093/mmy/myx101

19. Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucormycosisin 2023: an update on pathogenesis and management.Front Cell Infect Microbiol 2023; 13. doi: 10.3389/fcimb.2023.1254919

20. Smith C, Lee SC. Current treatments against mucormycosisand future directions. PLoS Pathog 2022; 18 (10). doi:10.1371/journal.ppat.1010858